CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 23 enrolled
Drug / intervention
Womed Leafdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04381728
NCT04381728N/ACompleted

PREvention of Intrauterine Adhesion After Hysteroscopic Surgery With Novel deGradable Film

Womed·interventional·Posted May 11, 2020·Updated Nov 9, 2021

In Brief

A clinical study evaluating Womed Leaf for Intrauterine Adhesion. Completed, enrolled 23 participants across 6 sites in 3 countries.

Detailed Summary

Intrauterine adhesions (IUA) are the major long-term complication of intrauterine procedures and are associated with pelvic pain, menstrual disorders, obstetrical complication and infertility. Womed Leaf is a medical device specifically designed for intrauterine use that prevents intra-uterine adhesions. It is a film that acts as a mechanical barrier to keep uterus walls separated during healing. It is then naturally discharged through the cervix and vagina in less than 30 days. The PREG1 clinical investigation is designed to evaluate Womed Leaf safety under clinical conditions, in women scheduled for a hysteroscopic myomectomy as well as its efficacy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesBelgium, France, Netherlands
Collaborators--

Timeline

N/ACompletedFinished
2020202120222023202420252026
First PostedMay 11, 2020
Enrollment StartNov 18, 2019
Primary CompletionMar 15, 2021
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 6.1 years ago

Interventions

Womed Leafdevice

Womed Leaf uterine film will be inserted immediately after the myomectomy, following per-operative hysterometry.